Nestlé and Danone Under Pressure as Infant Formula Crisis Deepens and Illnesses Rise

The infant formula crisis has expanded to include Danone (BN.PA) alongside Nestlé (NESN.SW), as both companies face intensifying scrutiny over product safety standards. Reports of illnesses have surged to include dozens of infants, compounding the gravity of ongoing investigations into previous fatalities linked to cereulide contamination. In response to the escalating scandal, investors are now demanding clear disclosure regarding the specific financial impact of the massive product recalls on both firms' earnings. Legal pressures remain high as French prosecutors continue their probe, placing the reputation of the core infant nutrition segment at significant risk. This development has further shaken investor confidence in the consumer staples sector, with market participants awaiting transparent turnaround strategies. Shares of both industry giants remain under pressure in European markets as the operational and legal challenges mount.